{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:03:34Z","timestamp":1788887014685,"version":"build-2803163510"},"reference-count":37,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1586\/14737140.6.6.861","type":"journal-article","created":{"date-parts":[[2006,6,8]],"date-time":"2006-06-08T16:29:28Z","timestamp":1149784168000},"page":"861-869","source":"Crossref","is-referenced-by-count":21,"title":["Ibritumomab tiuxetan for non-Hodgkin\u2019s lymphoma"],"prefix":"10.1586","volume":"6","author":[{"given":"Patrick B","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Bondly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana NM","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"CIT0002","first-page":"1763","volume":"12","author":"McLaughlin","year":"1998","journal-title":"Oncology"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.3816\/CLM.2004.s.006","volume":"5","author":"Micallef","year":"2004","journal-title":"Clin. Lymphoma"},{"key":"CIT0004","first-page":"1507","volume":"43","author":"Juweid","year":"2002","journal-title":"J. Nucl. Med."},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00107-X"},{"key":"CIT0006","first-page":"268","volume":"42","author":"Wiseman","year":"2001","journal-title":"J. Nucl. Med."},{"key":"CIT0007","unstructured":"Zevalin (ibritumomab tiuxetan) prescribing information. Biogen Idec Inc , Cambridge, MA, USA. (2002)."},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminoncol.2003.10.004","volume":"30","author":"Gregory","year":"2003","journal-title":"Semin. Oncol."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","volume":"2","author":"Grillo-Lopez","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/annonc\/mdi148","volume":"16","author":"Hagenbeek","year":"2005","journal-title":"Ann. Oncol."},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1053\/j.seminoncol.2005.01.013","volume":"32","author":"Grillo-Lopez","year":"2005","journal-title":"Semin. Oncol."},{"key":"CIT0012","first-page":"55a","volume":"86","author":"Grillo-Lopez","year":"1995","journal-title":"Blood"},{"key":"CIT0013","first-page":"457","volume":"2","author":"Knox","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"CIT0015","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"Witzig","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3816\/CLM.2004.n.015","volume":"5","author":"Gordon","year":"2004","journal-title":"Clin. Lymphoma"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/cbr.2004.19.478","volume":"19","author":"Schilder","year":"2004","journal-title":"Cancer Biother. Radiopharm."},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1200\/jco.2005.23.16_suppl.6562","volume":"23","author":"Schilder","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"579s","DOI":"10.1200\/jco.2005.23.16_suppl.6577","volume":"23","author":"Shipley","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"CIT0024","first-page":"406a","volume":"102","author":"Witzig","year":"2003","journal-title":"Blood"},{"key":"CIT0025","first-page":"135","volume":"16","author":"Wiseman","year":"2005","journal-title":"Ann. Oncol."},{"key":"CIT0026","first-page":"130","volume":"104","author":"Morschhauser","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"key":"CIT0027","first-page":"926","volume":"106","author":"Hamlin","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"CIT0028","first-page":"2632","volume":"104","author":"Oki","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"key":"CIT0029","first-page":"897","volume":"104","author":"Flinn","year":"2004","journal-title":"ASH Annual Meeting Abstracts"},{"key":"CIT0030","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood.V104.11.1162.1162","volume":"104","author":"Winter","year":"2004","journal-title":"Blood"},{"key":"CIT0031","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1200\/jco.2005.23.16_suppl.6566","volume":"23","author":"Krishnan","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1310"},{"key":"CIT0033","first-page":"30a","volume":"102","author":"Vose","year":"2003","journal-title":"Blood"},{"key":"CIT0034","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"Witzig","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"CIT0035","first-page":"357a","volume":"100","author":"Czuczman","year":"2002","journal-title":"Blood"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.143"},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CLM.2004.n.028","volume":"5","author":"Ansell","year":"2004","journal-title":"Clin. Lymphoma"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737140.6.6.861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T03:32:04Z","timestamp":1627443124000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737140.6.6.861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1586\/14737140.6.6.861"],"URL":"https:\/\/doi.org\/10.1586\/14737140.6.6.861","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}